The information provided on EL7.AI is for educational and informational purposes only and does not constitute financial advice.

We use cookies to improve your experience and serve personalized ads.

By clicking Accept, you consent to our use of advertising cookies. See our Privacy Policy for details.

StocksHigh ImpactUpdated•Originally published 15 April 2026•Updated 15 April 2026•

1 min read

Replimune Shares Crash 75% After FDA Rejects RP1 Biologics License Application

Fortified uniQure building, fences, caution tape, security cameras. FDA buildings, US flags, justice symbols. Charts on tablets and papers.

Key Facts

1The FDA rejected Replimune Group's Biologics License Application (BLA) for RP1 plus nivolumab due to trial design concerns.

about 2 months ago

Version History

Version 1about 2 months ago

Replimune Group (REPL) shares plummeted by 75.0% after the U.S. Food and Drug Administration (FDA) rejected its Biologics License Application (BLA) for the melanoma treatment candidate RP1. The regulator cited significant concerns regarding the design of the clinical trials used to support the drug's efficacy. This rejection serves as a major setback for the company, as RP1 was considered its primary value driver despite previous breakthrough designations. Investors are now grappling with heightened risks concerning cash flow sustainability and delayed approval timelines. The massive drop reflects a fundamental breakdown in market confidence and a substantial loss of market capitalization. Analysts are closely monitoring how the company will address the FDA's concerns and the subsequent impact on its long-term operational viability.